Press release
Primary Hyperoxaluria Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Precision Biosciences, Chinook Therapeutics, BridgeBio, OxThera
Primary Hyperoxaluria Clinical Trials
According to DelveInsight, the Primary Hyperoxaluria pipeline features over 6 key companies actively developing more than 6 therapeutic candidates for the treatment of Primary Hyperoxaluria.
Primary Hyperoxaluria Overview:
Primary hyperoxaluria type 1 (PH1) is a rare inherited disorder caused by a deficiency of the liver enzyme alanine-glyoxylate aminotransferase, leading to overproduction of oxalate. This results in excessive oxalate excretion in urine and the buildup of calcium oxalate in organs, particularly the kidneys. PH1 is the most common and severe form of primary hyperoxaluria, with an estimated prevalence of 1-3 cases per million and an incidence of 1 per 120,000 births annually in Europe.
The condition is marked by the formation of kidney stones, potential kidney damage, and systemic complications if left untreated. Typical symptoms include severe pain in the lower abdomen, groin, or back, discolored urine, painful or frequent urination, and systemic signs such as fever, nausea, and vomiting. Without proper management, PH1 can progress to kidney failure.
Primary hyperoxaluria arises from genetic mutations affecting glyoxylate metabolism: PH1 is linked to the AGXT gene, PH2 to GRHPR, and PH3 to HOGA1. Excess oxalate forms insoluble calcium oxalate deposits in multiple organs, including the kidneys, heart, blood vessels, skin, and bones, resulting in systemic oxalosis. Without effective treatment, the disease can lead to progressive renal and systemic complications.
Request for a detailed insights report on Primary Hyperoxaluria pipeline insights [https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Primary Hyperoxaluria Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Hyperoxaluria Therapeutics Market.
Key Takeaways from the Primary Hyperoxaluria Pipeline Report
*
DelveInsight's Primary Hyperoxaluria (PH) pipeline report highlights an active landscape, with over 6 companies developing more than 6 therapeutic candidates for the treatment of PH.
*
Leading companies-including Precision Biosciences, Chinook Therapeutics, BridgeBio, OxThera, and others-are actively evaluating new therapies to enhance the PH treatment landscape. Notable pipeline candidates in various stages of development include Oxabact and others.
*
In September 2023, the FDA approved nedosiran (Rivfloza) for patients aged nine and older with PH1 who have relatively preserved kidney function. This LDHA-targeted small interfering RNA therapy effectively reduces urinary oxalate levels.
*
Additionally, lumasiran, an RNA interference therapy, was approved in November 2020 by both the FDA and the European Union for the treatment of PH1 in adults and children. Clinical trials showed that lumasiran significantly lowered urinary oxalate levels in treated patients.
Primary Hyperoxaluria Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Primary Hyperoxaluria Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Primary Hyperoxaluria market.
Download our free sample page report on Primary Hyperoxaluria pipeline insights [https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Primary Hyperoxaluria Emerging Drugs
*
Oxabact: OxThera
Primary Hyperoxaluria Companies
Over six leading companies are actively developing therapies for Primary Hyperoxaluria, with OxThera having a drug candidate that has reached the most advanced stage of development, Phase III.
DelveInsight's report covers around 6+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Primary Hyperoxaluria Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Primary Hyperoxaluria Therapies and Key Companies: Primary Hyperoxaluria Clinical Trials and advancements [https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Primary Hyperoxaluria Pipeline Therapeutic Assessment
- Primary Hyperoxaluria Assessment by Product Type
- Primary Hyperoxaluria By Stage
- Primary Hyperoxaluria Assessment by Route of Administration
- Primary Hyperoxaluria Assessment by Molecule Type
Download Primary Hyperoxaluria Sample report to know in detail about the Primary Hyperoxaluria treatment market @ Primary Hyperoxaluria Therapeutic Assessment [https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Primary Hyperoxaluria Current Treatment Patterns
4. Primary Hyperoxaluria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Hyperoxaluria Late-Stage Products (Phase-III)
7. Primary Hyperoxaluria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Hyperoxaluria Discontinued Products
13. Primary Hyperoxaluria Product Profiles
14. Primary Hyperoxaluria Key Companies
15. Primary Hyperoxaluria Key Products
16. Dormant and Discontinued Products
17. Primary Hyperoxaluria Unmet Needs
18. Primary Hyperoxaluria Future Perspectives
19. Primary Hyperoxaluria Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Primary Hyperoxaluria Pipeline Reports Offerings [https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-hyperoxaluria-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-precision-biosciences-chinook-therapeutics-bridgebio-oxthera]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Hyperoxaluria Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Precision Biosciences, Chinook Therapeutics, BridgeBio, OxThera here
News-ID: 4162676 • Views: …
More Releases from ABNewswire
Frish Law Group APLC Provides Steadfast Personal Injury Advocacy in Hollywood Hi …
Los Angeles, CA - August 28, 2025 - In the heart of Los Angeles, traffic collisions, workplace accidents, and unexpected injuries can disrupt lives in an instant. For many residents of Hollywood Hills and Central LA, Frish Law Group, APLC has become a reliable source of legal support, offering compassionate guidance and effective representation when it matters most.
The firm is known not only for its courtroom skill but also for…
Frish Law Group APLC Highlights Dedication to Personal Injury Representation in …
Woodland Hills, CA - August 28, 2025 - For families in Woodland Hills, the days and weeks after an accident often come with medical appointments, insurance calls, and overwhelming uncertainty. During these moments, Frish Law Group, APLC has become a dependable ally, guiding injury victims through complex legal challenges and toward fair compensation.
The firm has developed a strong reputation in Los Angeles County by focusing on the details that matter…
Primary Biliary Cholangitis Clinical Trials, Companies, Therapeutic Assessment, …
DelveInsight's, "Primary Biliary Cholangitis (PBC)- Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis (PBC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Primary Biliary Cholangitis…
Sell Fire Damaged House Reports Record Increase in Homeowners Seeking Quick Sale …
Sell Fire Damaged House, a California homebuyer focusing on fire - impacted qualities, reports a record uptick of homeowners requesting quick, as is sales like wildfire losses rise throughout the state.
Sell Fire Damaged House [https://www.sellfiredamagedhouseca.com/], a California homebuyer focusing on fire - impacted qualities, reports a record uptick of homeowners requesting quick, as is sales like wildfire losses rise throughout the state.
Wildfire Losses Drive Record Seller Inquiries
The need for certainty…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
